AGEN Agenus Inc.

2.42
-0.08  -3%
Previous Close 2.5
Open 2.5
Price To Book -2.22
Market Cap 290358775
Shares 119,982,965
Volume 799,750
Short Ratio
Av. Daily Volume 1,136,796

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 enrolment to be completed 2019.
AGEN2034 and AGEN1884
Solid tumors
Phase 1 presentation at ASCO 2018. 31% ORR.
AGEN1884 (anti-CTLA-4)
Solid cancers
Approval announced October 20, 2017.
Shingrix
Shingles
Phase 1 data presented at ESMO October 2018 noted clinical benefit of 3/7 cervical cancer patients.
AGEN2034 (anti-PD-1)
Cervical cancer
Phase 1/2 trial initiation announced November 30, 2016.
INCAGN1949
Solid tumors - cancer
Phase 1/2 trial commenced June 2016
INCAGN1876
Solid tumors - cancer

Latest News

  1. Why Is Agenus (AGEN) Up 11.6% Since Last Earnings Report?
  2. Here's Why Agenus Stock Popped 51.6% in November
  3. Orchestra BioMed™ Appoints C. Evan Ballantyne as Chief Financial Officer
  4. Edited Transcript of AGEN earnings conference call or presentation 6-Nov-18 1:30pm GMT
  5. Agenus Elects New Board Member Dr. Allison Jeynes-Ellis and Appoints Chief Operating Officer Dr. Jennifer Buell
  6. Agenus to Present at the 2018 Jefferies London Healthcare Conference
  7. Report: Developing Opportunities within Agenus, Kirkland's, Preferred Apartment Communities, Gulfport Energy, ProAssurance, and US Ecology — Future Expectations, Projections Moving into 2018
  8. Agenus (AGEN) Q3 Loss Wider Than Expected, Pipeline in Focus
  9. Agenus to Present Data on Neoantigen Vaccines and anti-CD137 Antibody at SITC 2018
  10. Agenus (AGEN) Reports Q3 Loss, Tops Revenue Estimates
  11. Agenus: 3Q Earnings Snapshot
  12. Agenus Reports Third Quarter 2018 Financial Results and Provides Corporate Update
  13. Agenus to Report Third Quarter 2018 Financial Results on November 6, 2018 and Host Conference Call and Webcast
  14. Will Agenus (AGEN) Report Negative Earnings Next Week? What You Should Know
  15. Agenus Presents Clinical Data on Its PD-1 & CTLA-4 at ESMO 2018
  16. Agenus To Present Data on Proprietary CTLA-4 & PD-1 Antibodies at ESMO 2018
  17. Recent Analysis Shows Ryman Hospitality Properties, PennantPark Investment, PS Business Parks, Agenus, Belden, and Robert Half International Market Influences — Renewed Outlook, Key Drivers of Growth
  18. Celyad (CYAD) Jumps: Stock Rises 6.8%
  19. Agenus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York, NY
  20. Agenus Closes $15 Million Partial Royalty Monetization With XOMA

SEC Filings

  1. EFFECT - Notice of Effectiveness 181227723
  2. CT ORDER - Confidential treatment order 181215524
  3. 8-K - Current report 181178060
  4. S-3 - Registration statement under Securities Act of 1933 181169926
  5. S-8 - Securities to be offered to employees in employee benefit plans 181169815
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166567
  7. 8-K - Current report 181161495
  8. D - Notice of Exempt Offering of Securities 181138959
  9. 8-K - Current report 181117390
  10. 8-K - Current report 181080514